8 Amendments of Carl SCHLYTER related to 2011/0401(COD)
Amendment 125 #
Proposal for a regulation
Article 16 – paragraph 3 – point c a (new)
Article 16 – paragraph 3 – point c a (new)
(ca) research classified as causing severe suffering to vertebrate animals;
Amendment 127 #
Proposal for a regulation
Article 16 – paragraph 3 – point c b (new)
Article 16 – paragraph 3 – point c b (new)
(cb) involving wild-caught or F1 non- human primates;
Amendment 128 #
Proposal for a regulation
Article 16 – paragraph 3 – point c c (new)
Article 16 – paragraph 3 – point c c (new)
(cc) research on mammals or birds involving deliberate maternal deprivation;
Amendment 136 #
Proposal for a regulation
Article 16 – paragraph 4 a (new)
Article 16 – paragraph 4 a (new)
4a. Research on animal testing falling within the scope of Directive 2010/63/EU on the protection of animals used for scientific purposes shall be subject to a rigorous and transparent ethical and scientific merit review process, including full substantiation of claims regarding the relevance of animal models to the human situation.
Amendment 169 #
Proposal for a regulation
Annex I – part I – point 2.3 – paragraph 2 – point a
Annex I – part I – point 2.3 – paragraph 2 – point a
(a) By fostering novel ideas (‘FET Open’), FET shall support embryonicerging science and technology research exploring new foundations for radically new future technologies by challenging current paradigms, such as the use of animal models in biomedical research or for the testing of chemicals for adverse effects on human health, and venturing into unknown areas. A bottom-up selection process widely open to any research ideas shall build up a diverse portfolio of targeted projects. Early detection of promising new areas, developments and trends, along with attracting new and high- potential research and innovation players, will be key.
Amendment 183 #
Proposal for a regulation
Annex I – part II – point 1.2.1. – introductory paragraph
Annex I – part II – point 1.2.1. – introductory paragraph
The specific objective of nanotechnologies research and innovation is to secure Union leadership in this high growth global market, by stimulating investment in safe and responsible nanotechnologies and their uptake in high added-value, competitive products and services across a range of applications and sectors.
Amendment 193 #
Proposal for a regulation
Annex I – part II – point 1.2.3. – point b – paragraph 1
Annex I – part II – point 1.2.3. – point b – paragraph 1
Advancing scientific knowledge of the potential impact of nanotechnologies and nanosystems on health or on the environment, and providing fit-for purpose non-animal tools for risk assessment and management along the entire life cycle.
Amendment 260 #
Proposal for a regulation
Annex I – part III – point 1.1 – paragraph 6
Annex I – part III – point 1.1 – paragraph 6
Meanwhile, drug and vaccine development processes are becoming more expensive and less effective, and the validity of the underlying animal tests for humans more and more challenged. Their regulatory science needs to be improved. Persistent health inequalities must be addressed, and access to effective and competent health systems must be ensured for all Europeans.